MWNA
ALXN

Marshall Wace North America’s Alexion Pharmaceuticals ALXN Stock Holding History

Marshall Wace North America’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,643
Closed -$301K – 1861
2021
Q2 		$301K Buy
+1,643
New +$282K ﹤0.01% 1281
2021
Q1 		– Sell
-642,648
Closed -$100M – 1903
2020
Q4 		$100M Buy
642,648
+637,683
+12,844% +$81.9M 0.45% 42
2020
Q3 		$568K Sell
4,965
-152,766
-97% -$16.5M ﹤0.01% 941
2020
Q2 		$17.7M Buy
157,731
+145,334
+1,172% +$15.4M 0.12% 194
2020
Q1 		$1.11M Sell
12,397
-190,805
-94% -$18.7M 0.01% 600
2019
Q4 		$22M Sell
203,202
-147,587
-42% -$15.8M 0.11% 191
2019
Q3 		$34.4M Sell
350,789
-16,565
-5% -$1.87M 0.2% 121
2019
Q2 		$48.1M Sell
367,354
-248,883
-40% -$32.1M 0.3% 91
2019
Q1 		$83.3M Buy
616,237
+193,470
+46% +$24.1M 0.59% 47
2018
Q4 		$41.2M Buy
422,767
+23,475
+6% +$2.77M 0.4% 70
2018
Q3 		$55.5M Sell
399,292
-605,877
-60% -$76M 0.38% 66
2018
Q2 		$125M Sell
1,005,169
-79,722
-7% -$9.32M 0.7% 24
2018
Q1 		$121M Buy
1,084,891
+982,419
+959% +$117M 0.61% 31
2017
Q4 		$12.3M Sell
102,472
-2,311
-2% -$281K 0.07% 331
2017
Q3 		$14.7M Sell
104,783
-7,515
-7% -$1.02M 0.09% 280
2017
Q2 		$13.7M Sell
112,298
-426,704
-79% -$49.7M 0.1% 252
2017
Q1 		$65.2M Buy
+539,002
New +$69.5M 0.51% 41
2013
Q4 		$4.05M Buy
+30,427
New +$3.65M 0.09% 208

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Marshall Wace North America's ALXN Position: Q3 2021 in Review

Marshall Wace North America sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,643 shares — an estimated $301K sold.

Marshall Wace North America first reported a position in ALXN in Q4 2013 and held it in 18 quarters. The position peaked at $125M in Q2 2018. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Marshall Wace North America reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 1,643 Alexion Pharmaceuticals shares in Q3 2021, an estimated $301K.
  • Marshall Wace North America first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 18 quarters.
  • Marshall Wace North America's Alexion Pharmaceuticals position peaked at $125M in Q2 2018.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.